365 results on '"Jacoby, Meagan A."'
Search Results
52. Daratumumab in transfusion‐dependent patients with low or intermediate‐ 1 risk myelodysplastic syndromes
53. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
54. Hand-foot syndrome following decitabine
55. Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
56. Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351
57. Comparison of Deep Whole Exome Versus Targeted Gene Sequencing for Assessment of Persistent Molecular Disease in Acute Myeloid Leukemia Samples
58. Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML
59. MDS-141: The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study
60. 3. Use of a targeted gene panel to inform treatment decisions for patients with AML
61. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome
62. Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS
63. A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome
64. 386 - A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
65. A phase I study of AMV564 in patients with intermediate or high-risk myelodysplastic syndromes.
66. A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
67. Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance
68. Exome analysis of treatment‐related AML after APL suggests secondary evolution
69. Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy
70. Mutation Clearance after Transplantation for Myelodysplastic Syndrome
71. CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS.
72. Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.
73. Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant
74. Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML
75. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen
76. Dynamic Changes in MDS Clonal Architecture Following Allogeneic Stem Cell Transplant
77. Rare Pre-Existing MDS Subclones Contribute to Secondary AML Progression
78. Deleterious Germline Mutations in Telomere Maintenance Genes Identified in a Subset of Patients with Myelodysplastic Syndrome and Idiopathic Pulmonary Fibrosis
79. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
80. Exome analysis of treatment‐related AML after APL suggests secondary evolution.
81. Reduced Subclone Diversity in Clonal Cytopenia of Undetermined Significance Compared to Myelodysplastic Syndrome
82. Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes
83. Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation
84. Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia
85. A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome
86. Detection of Clonal Hematopoiesis in Cytopenic Patients Using Targeted Sequencing
87. Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)
88. Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients
89. Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy
90. Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes
91. A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome
92. Hand-foot syndrome following decitabine
93. A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia
94. Ultra-Deep Sequencing As a Predictive Tool for MDS Progression after Allogeneic Hematopoietic Cell Transplant
95. A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
96. Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation
97. Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation
98. A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS
99. The impact of CD34+ cell dose and comorbidities on engraftment following autologous hematopoietic stem cell transplantation (ASCT).
100. Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.